ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

businesswire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer – NEWSnet – News… as it used to be

More Press Releases

June 1, 2026

New Navigation Technology Available from HRL Laboratories

June 1, 2026

E.F. Hutton & Co. Promotes Geoffrey D. Liddy to Chief Operating Officer

June 1, 2026

IDE Technologies Secures Bid for Largest Seawater Desalination Facility in Western Hemisphere

June 1, 2026

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

New Navigation Technology Available from HRL Laboratories

E.F. Hutton & Co. Promotes Geoffrey D. Liddy to Chief Operating Officer

IDE Technologies Secures Bid for Largest Seawater Desalination Facility in Western Hemisphere

Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for May 2026, includes Reg.-NMS Execution Statistics